EUVIMEDEUVIMED entdecken
ÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post hoc analysis of the Hokusai venous thromboembolism cancer study

Vincent R Lanting, Kika van Bergen En Henegouwen, Floris T M Bosch, Michael A Grosso, Annelise Segers, Gary E Raskob, T Pieter Willem Kamphuisen, Harry R Büller, Peter Verhamme, Jeffrey I Weitz, Marcello Di Nisio, Marc Carrier und 2 weitere

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2025.02.022 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Vincent R Lanting und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Medicine, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Meibergdreef, Amsterdam, the Netherlands;…. Hauptthemen laut MEDLINE: Anticoagulants, Dalteparin, Factor Xa Inhibitors, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amsterdam University Medical Centres.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The management of recurrent venous thromboembolism (VTE) despite anticoagulant treatment in patients with cancer is uncertain. To address this, we used data from the Hokusai VTE Cancer trial, which compared edoxaban with dalteparin to treat cancer-associated VTE. OBJECTIVES: To characterize and evaluate anticoagulant treatment strategies during and after on-treatment recurrent VTE, including the type and dose of anticoagulant. METHODS: In this post hoc analysis, all patients with adjudicated on-treatment recurrent VTE within 12 months after randomization were included. Outcomes were second recurrent VTE and major bleeding within 3 months after the first recurrent VTE. RESULTS: A total of 67 patients developed on-treatment recurrent VTE while receiving therapeutic-dose edoxaban (31%), therapeutic-dose low-molecular-weight heparin (LMWH) (34%), maintenance-dose LMWH (21%), or other therapies (14%). After the recurrent event, 28 patients (42%) received an increased dose, 35 (52%) a comparable dose, and 4 (6%) a reduced dose or stopped anticoagulants. Common treatment regimens included supratherapeutic-dose LMWH (21%), therapeutic-dose LMWH (51%), direct oral anticoagulants (16%), or another treatment strategy (12%). In the 3 months after recurrent VTE, 6 (9%) patients had a second recurrence and 7 (10%) had major bleeding. CONCLUSION: Treatment strategies for recurrent VTE in patients with cancer are heterogeneous. The risk of a second recurrence and major bleeding are considerable. More studies are needed to determine the optimal treatment strategy for recurrent cancer-associated thrombosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsDalteparinFactor Xa InhibitorsNeoplasmsPyridinesThiazolesVenous ThromboembolismAgedFemaleHumansMaleMiddle AgedHemorrhageHeparin, Low-Molecular-WeightJapanRecurrenceRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Anticoagulantsdirect oral anticoagulantslow molecular weight heparinneoplasmsvenous thromboembolism

Substanzen

AnticoagulantsDalteparinedoxabanFactor Xa InhibitorsHeparin, Low-Molecular-WeightPyridinesThiazoles

Autor:innen und Institutionen

  • Department of Vascular Medicine, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Meibergdreef, Amsterdam, the Netherlands; Department of Internal Medicine, Tergooi MC, Laan van Tergooi, Hilver…
  • Department of Vascular Medicine, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Meibergdreef, Amsterdam, the Netherlands.
  • Clinical Development, Daiichi Sankyo, Basking Ridge, New Jersey, USA.
  • International Trial Expertise Advisory and Services (ITREAS), Amsterdam, the Netherlands.
  • University of Oklahoma Health Sciences Center and OU Health, Oklahoma City, Oklahoma, USA.
  • Department of Cardiovascular Diseases, University Hospitals Leuven, Herestraat, Leuven, Belgium.

Förderung

  • Amsterdam University Medical Centres

Zitieren

APA

Lanting, V. R., van Bergen En Henegouwen, K., Bosch, F. T. M., Grosso, M. A., Segers, A., Raskob, G. E., Kamphuisen, T. P. W., Büller, H. R., Verhamme, P., Weitz, J. I., Di Nisio, M., Carrier, M., van Es, N., & Wang, T. F. (2025). Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post hoc analysis of the Hokusai venous thromboembolism cancer study. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.02.022

Vancouver

Lanting VR, van Bergen En Henegouwen K, Bosch FTM, Grosso MA, Segers A, Raskob GE, et al. Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post hoc analysis of the Hokusai venous thromboembolism cancer study. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.02.022

BibTeX
@article{Lanting2025,
  author = {Lanting, Vincent R and van Bergen En Henegouwen, Kika and Bosch, Floris T M and Grosso, Michael A and Segers, Annelise and Raskob, Gary E and Kamphuisen, T Pieter Willem and Büller, Harry R and Verhamme, Peter and Weitz, Jeffrey I and Di Nisio, Marcello and Carrier, Marc and van Es, Nick and Wang, Tzu-Fei},
  title = {Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post hoc analysis of the Hokusai venous thromboembolism cancer study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2025.02.022}
}
Kostenlos starten →